The effects of ezetimibe on surrogate markers of cholesterol absorption and synthesis in Japanese patients with dyslipidemia

Journal of Atherosclerosis and Thrombosis

Volumn 17, Issue 1, 2010, Pages 106-114

  Hiramitsu, Shinya ^a   Ishiguro, Yoshiaki ^a   Matsuyama, Hiroyuki ^a   Yamada, Kenji ^a   Kato, Kazuo ^a   Noba, Manji ^a   Uemura, Akihisa ^a   Yoshida, Satoshi ^a   Matsubara, Yoshiro ^a   Kani, Atsushi ^a   Hasegawa, Kazuo ^a   Hishida, Hitoshi ^a,b   Ozaki, Yukio ^a,b  

^a Fujita Ezetimibe STudy Assembly (FESTA) Investigators Group   (Japan)

^b FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Absorption; Cholesterol; Ezetimibe; Synthesis

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; CHOLESTEROL; EZETIMIBE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; STATIN; TRIACYLGLYCEROL;

AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CHOLESTEROL TRANSPORT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIET THERAPY; DISEASE MARKER; DRUG EFFECT; DRUG SAFETY; DYSLIPIDEMIA; ENZYME BLOOD LEVEL; EXERCISE; FEMALE; GLUCOSE METABOLISM; HUMAN; INFLAMMATION; INSULIN BLOOD LEVEL; INTESTINE ABSORPTION; JAPANESE; LIPID BLOOD LEVEL; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OBESITY; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 76249107102     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.1578     Document Type: Article

References (26)

1. Endo A: HMG-CoA reductase inhibitors. Adv Exp Med Biol, 1985; 183: 295-310
2. Altmann SW, Davis HR Jr, Zhu LJ, Yao X, Hoos LM, Tetzloff G, Iyer SP, Maguire M, Golovko A, Zeng M, Wang L, Murgolo N, Grazian: Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science, 2004; 303: 1201-1204
3. Harris M, Davis W, Brown WV: Ezetimibe. Drugs Today (Barc), 2003; 39: 229-247
4. Miettinen TA, Gylling H, Strandberg T, Sarna S: Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study. BMJ, 1988; 316: 1127-1130
5. Strandberg TE, Tilvis RS, Pitkala KH, Miettinen TA: Cholesterol and Glucose Metabolism and Recurrent Cardiovascular Events among the Elderly: a prospective study. J Am Coll Cardiol, 2006; 48: 708-714
6. Gylling H, Miettinen TA: Cholesterol absorption and lipoprotein metabolism in type II diabetes mellitus with and without coronary artery disease. Atherosclerosis, 1996; 126: 325-332
7. Mok HY, von Bergmann K, Grundy SM: Effects of continuous and intermittent feeding on biliary lipid outputs in man: application for measurements of intestinal absorption of cholesterol and bile acids. J Lipid Res, 1979; 20: 389-398
8. Lally S, Tan CY, Owens D, Tomkin GH: Messenger RNA levels of genes involved in dysregulation of postprandial lipoproteins in type 2 diabetes: the role of Niemann-Pick C1-like 1, ATP-binding cassette, transporters G5 and G8, and of microsomal triglyceride transfer protein. Diabetologia, 2006; 49: 1008-1016
9. Japan Atherosclerosis Society: Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases. J Atheroscler Thromb, 2007; 5-57
10. Miettinen TA, Ahrens EH, Grundy SM: Quantitative isolation and gas-liquid chromatographic analysis of total dietary and fecal neutral steroids. J Lipid Res, 1965; 6: 441-424
11. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia west of Scotland coronary Prevention Study Group. N Engl J Med, 1995; 333: 1301-1307
12. Scandinavian Simvastatin Survival Study Group: Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 1994; 344: 1383-1389
13. Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, Nakaya N, Nishimoto S, Muranaka M, Yamamoto A, Mizuno K, Ohashi Y; MEGA Study Group: Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomized controlled trial. Lancet, 2006; 368: 1155-1163
14. Kesäniemi YA, Miettinen TA: Cholesterol absorption efficiency regulates plasma cholesterol level in the Finnish population. Eur J Clin Invest, 1987; 17: 391-395
15. National Cardiovascular Survey in Japan by MHW 2000
16. National Nutrition & Health Survey by MHLW 1998
17. Tsuji E: Dietary cholesterol intake in the Japanese population. Geriatr Med, 2007; 45: 1511-1515
18. Melani L, Mills R, Hassman D, Lipetz R, Lipka L, LeBeaut A, Suresh R, Mukhopadhyay P, Veltri E; Ezetimibe Study Group: Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Eur Heart J, 2003; 24: 717-728
19. Deushi M, Nomura M, Kawakami A, Haraguchi M, Ito M, Okazaki M, Ishii H, Yoshida M: Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. FEBS Lett, 2007; 581: 5664-5670
20. Matsuzawa Y, Funahashi T, Nakamura T: Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances. Ann N Y Acad Sci, 1999; 892: 146-154]
21. Grundy SM: Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am J Cardiol, 1999; 83: 25F-29F
22. Miettinen TA, Gylling H, Lindbohm N, Miettinen TE, Rajaratnam RA, Relas H; Finnish Treat-to-Target Study Investigators: Serum noncholesterol sterols during inhibition of cholesterol synthesis by statins. J Lab Clin Med, 2003; 141: 131-137
23. Pearson TA, Denke MA, McBride PE, Battisti WP, Brady WE, Palmisano J: A Community-Based, Randomized Trial of Ezetimibe Added to Statin Therapy to Attain NCEP ATP III Goals for LDL Cholesterol in Hypercholesterolemic Patients: The Ezetimibe Add-On to Statin for Effectiveness (EASE) Trial. Mayo Clin Proc, 2003; 80: 587-595
24. Pisciotta L, Fasano T, Bellocchio A, Bocchi L, Sallo R, Fresa R, Colangeli I, Cantafora A, Calandra S, Bertolini S: Effect of ezetimibe coadministerd with statins in genotype-confirmed heterozygous FH patients. Atherosclerosis, 2007; 194: e116-122
25. Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R, Sun S, LeBeaut AP, Sager PT, Veltri EP; Ezetimibe Study Group: Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia a prospective, randomized, deuble-blind trial. Circulation, 2003; 107: 2409-2415
26. Davidson MH, Ballantyne CM, Kerzner B, Melani L, Sager PT, Lipka L, Strony J, Suresh R, Veltri E; Ezetimibe Study Group: Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int J Clin Pract, 2004; 58: 746-755